224 related articles for article (PubMed ID: 26787513)
1. Antisense targeting of 3' end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach.
Marsollier AC; Ciszewski L; Mariot V; Popplewell L; Voit T; Dickson G; Dumonceaux J
Hum Mol Genet; 2016 Apr; 25(8):1468-78. PubMed ID: 26787513
[TBL] [Abstract][Full Text] [Related]
2. Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics.
Chen JC; King OD; Zhang Y; Clayton NP; Spencer C; Wentworth BM; Emerson CP; Wagner KR
Mol Ther; 2016 Aug; 24(8):1405-11. PubMed ID: 27378237
[TBL] [Abstract][Full Text] [Related]
3. Antisense Oligonucleotide Targeting of 3'-UTR of mRNA for Expression Knockdown.
Golshirazi G; Ciszewski L; Lu-Nguyen N; Popplewell L
Methods Mol Biol; 2018; 1828():91-124. PubMed ID: 30171537
[TBL] [Abstract][Full Text] [Related]
4. A distal auxiliary element facilitates cleavage and polyadenylation of Dux4 mRNA in the pathogenic haplotype of FSHD.
Peart N; Wagner EJ
Hum Genet; 2017 Sep; 136(9):1291-1301. PubMed ID: 28540412
[TBL] [Abstract][Full Text] [Related]
5. DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Bittel A; Maruyama R; Echigoya Y; Nguyen Q; Huang Y; Dzierlega K; Zhang A; Chen YW; Yokota T
Mol Ther; 2021 Feb; 29(2):848-858. PubMed ID: 33068777
[TBL] [Abstract][Full Text] [Related]
6. The FSHD atrophic myotube phenotype is caused by DUX4 expression.
Vanderplanck C; Ansseau E; Charron S; Stricwant N; Tassin A; Laoudj-Chenivesse D; Wilton SD; Coppée F; Belayew A
PLoS One; 2011; 6(10):e26820. PubMed ID: 22053214
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of
Lim KRQ; Maruyama R; Echigoya Y; Nguyen Q; Zhang A; Khawaja H; Sen Chandra S; Jones T; Jones P; Chen YW; Yokota T
Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16509-16515. PubMed ID: 32601200
[TBL] [Abstract][Full Text] [Related]
8. Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy.
Bittel AJ; Sreetama SC; Bittel DC; Horn A; Novak JS; Yokota T; Zhang A; Maruyama R; Rowel Q Lim K; Jaiswal JK; Chen YW
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759720
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Polyadenylation Signal of Pre-mRNA: A New Gene Silencing Approach for Facioscapulohumeral Dystrophy.
Marsollier AC; Joubert R; Mariot V; Dumonceaux J
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29751519
[TBL] [Abstract][Full Text] [Related]
10. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
Gatica LV; Rosa AL
Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
[TBL] [Abstract][Full Text] [Related]
11. Control of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Cancer.
Karpukhina A; Tiukacheva E; Dib C; Vassetzky YS
Trends Mol Med; 2021 Jun; 27(6):588-601. PubMed ID: 33863674
[TBL] [Abstract][Full Text] [Related]
12. Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.
Lu-Nguyen N; Malerba A; Herath S; Dickson G; Popplewell L
Hum Mol Genet; 2021 Jul; 30(15):1398-1412. PubMed ID: 33987655
[TBL] [Abstract][Full Text] [Related]
13. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy.
Himeda CL; Jones TI; Virbasius CM; Zhu LJ; Green MR; Jones PL
Mol Ther; 2018 Jul; 26(7):1797-1807. PubMed ID: 29759937
[TBL] [Abstract][Full Text] [Related]
14. Knocking Down DUX4 in Immortalized Facioscapulohumeral Muscular Dystrophy Patient-Derived Muscle Cells.
Lim KRQ; Yokota T
Methods Mol Biol; 2023; 2587():197-208. PubMed ID: 36401032
[TBL] [Abstract][Full Text] [Related]
15. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei.
Vanderplanck C; Tassin A; Ansseau E; Charron S; Wauters A; Lancelot C; Vancutsem K; Laoudj-Chenivesse D; Belayew A; Coppée F
Skelet Muscle; 2018 Jan; 8(1):2. PubMed ID: 29329560
[TBL] [Abstract][Full Text] [Related]
17. Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions.
Statland JM; Tawil R
Curr Opin Neurol; 2011 Oct; 24(5):423-8. PubMed ID: 21734574
[TBL] [Abstract][Full Text] [Related]
18. Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD).
Ansseau E; Vanderplanck C; Wauters A; Harper SQ; Coppée F; Belayew A
Genes (Basel); 2017 Mar; 8(3):. PubMed ID: 28273791
[TBL] [Abstract][Full Text] [Related]
19. The Role of D4Z4-Encoded Proteins in the Osteogenic Differentiation of Mesenchymal Stromal Cells Isolated from Bone Marrow.
de la Kethulle de Ryhove L; Ansseau E; Nachtegael C; Pieters K; Vanderplanck C; Geens M; Sermon K; Wilton SD; Coppée F; Lagneaux L; Belayew A
Stem Cells Dev; 2015 Nov; 24(22):2674-86. PubMed ID: 26192274
[TBL] [Abstract][Full Text] [Related]
20. CRISPR mediated targeting of DUX4 distal regulatory element represses DUX4 target genes dysregulated in Facioscapulohumeral muscular dystrophy.
Das S; Chadwick BP
Sci Rep; 2021 Jun; 11(1):12598. PubMed ID: 34131248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]